Ruprecht-Karls-Universitat-Heidelberg Patent applications |
Patent application number | Title | Published |
20160108376 | ABHD5 AND PARTIAL HDAC4 FRAGMENTS AND VARIANTS AS A THERAPEUTIC APPROACH FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure. | 04-21-2016 |
20160052954 | COMPOUNDS AND METHODS ASSOCIATED WITH DIFFERENTIAL METHYLATION OF HUMAN PAPILLOMA VIRUS GENOMES IN EPITHELIAL CELLS - The invention relates to compounds and methods useful in detection and therapy of HPV-associated diseases. The invention is based on the elucidation of a mechanism by which replication of HPVs occurs in naturally infected tissues and cells. Moreover it is based on the identification of distinct epigenetic changes of the viral genome in infected cells that allows promotion of the affected cells to precancerous and cancerous cells. The invention therefore provides methods of diagnosing neoplasias and their precursor lesions as well as methods of preventing the development of malignancies or inhibiting tumor growth. | 02-25-2016 |
20160047829 | Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample - The present invention relates to a method for determining a clearance normalized amount of a metabolite disease biomarker in a sample including the steps of (a) determining the amount of the disease biomarker in at least a first type of sample of a subject suspected to suffer from the disease, (b) determining the amount of a kidney function biomarker which correlates with the glomerular filtration rate (GFR) in the said at least first type of sample, and (c) determining a clearance normalized amount for the metabolite disease biomarker by normalizing the amount determined for the metabolite disease biomarker in step (a) to the amount of the kidney function biomarker determined in step (b). Moreover, the invention also relates to a method for diagnosing a disease in a subject suspected to suffer therefrom and to a device for determining a clearance normalized amount of a metabolite disease biomarker in a sample. | 02-18-2016 |
20150197812 | CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER - The present invention is directed to methods for diagnosing breast cancer, metastasizing breast cancer, or for determining the CTC status in a subject. Moreover, the present invention is concerned with devices and kits for carrying methods of the invention. The methods comprise determining in a sample of a subject suspected to be afflicted with breast cancer the amount of at least one miRNA selected from a recited list of miRNAs, followed by comparing the amount with one or more references, whereby breast cancer is to be diagnosed. | 07-16-2015 |
20150110715 | Double-Labeled Probe for Molecular Imaging and Use Thereof - The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof. | 04-23-2015 |
20150044716 | MEANS AND METHODS FOR THE DETERMINATION OF (D)-2-HYDROXYGLUTARATE (D2HG) OR (D)-2-HYDROXYADIPIC ACID - The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject. In addition, the invention provides for a kit comprising (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor. | 02-12-2015 |
20140343445 | System and Computer Program Product for Automatically Distinguishing Atrial Flutter from Atrial Fibrillation - The present invention relates to a system for automatically distinguishing atrial flutter from atrial fibrillation based on a sequence of R-R-intervals of ECG-data. The system of the invention comprises means adapted to calculate or simulate an R-R-pattern from a model which is based on a periodic or almost periodic signal representing peaks of an atrial flutter signal, a first AV block scheme blocking respective ones of the atrial excitations while transmitting the others with a predetermined transmittal delay and at least one more AV-block scheme blocking respective ones of the excitations transmitted by the previous AV-block scheme and transmitting the others with a predetermined transmittal delay. The excitations transmitted by the last AV-block scheme constitute the calculated R-R-pattern. The system further comprises consistency checking means adapted to automatically check whether said sequence of R-R-intervals of the ECG-data is to some predetermined degree consistent with said calculated or simulated pattern. The system is configured to identify the ECG-data to be based on atrial flutter if said predetermined degree of consistency is found. | 11-20-2014 |
20140207881 | CIRCUIT ARRANGEMENT FOR CONNECTION INTERFACE - The invention relates to a connecting interface having a circuit arrangement, in order to associate incoming data messages with available information, having a means for comparing incoming messages with available information and for storing available information. In this case, the means comprises a multiplicity of comparison elements that have a respective associated memory, wherein the respective memories together form a store for storing information relating to unassociated messages, and the comparison elements are designed for the parallel comparison of incoming messages with the information stored in their respective memories. | 07-24-2014 |
20140170179 | P16INK4A DERIVED PEPTIDES FOR PROPHYLAXIS AND THERAPY OF HPV-ASSOCIATED TUMORS AND OTHER P16INK4A EXPRESSING TUMORS - Described are particular fragments of the cyclin-dependent kinase inhibitor p16 capable of increasing IFN-γ secretion of T cells or inducing proliferation of T cells and the use of said fragments for immunizing an individual against HPV-associated or other p16 | 06-19-2014 |
20140170178 | MSI-SPECIFIC FRAMESHIFT PEPTIDES (FSP) FOR PREVENTION AND TREATMENT OF CANCER - Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer. | 06-19-2014 |
20140044741 | B-TYPE PLEXIN ANTAGONISTS AND USES THEREOF - The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide. | 02-13-2014 |
20130323276 | MALARIA VACCINES BASED ON PRE-ERYTHROCYTIC ANTIGENS FROM P. FALCIPARUM - The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides or fragments thereof, and the use of such compositions as malaria vaccines. | 12-05-2013 |
20130303550 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS - Compounds of formula (IIc); wherein X | 11-14-2013 |
20130296344 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS - Compounds according to the general formula (I) wherein X | 11-07-2013 |
20130209413 | USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs) - Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells. | 08-15-2013 |
20130189725 | HUMAN IN VITRO MODEL OF THE BLOOD CEREBROSPINAL FLUID BARRIER - The present invention relates to a human in vitro model system of the blood cerebrospinal fluid barrier (BCSFB), to a method for producing said model system, as well as to uses thereof. | 07-25-2013 |
20120294856 | COMPOUNDS INHIBITING CD95 SIGNALING FOR THE TREATMENT OF PANCREATIC CANCER - The present invention is concerned with compounds inhibiting CD95 signaling in pancreatic cancer cells. Furthermore, contemplated by the current invention are medicaments comprising such a compound for the prevention and/or treatment of pancreatic cancer as well as the use of such a compound for the manufacture of a medicament for the prevention and/or treatment of pancreatic cancer, the prevention of migration of cancer cells, and/or the prevention and/or treatment of an inflammatory reaction. The present invention also refers to a method for the identification of a compound inhibiting CD95 signaling, as we to a method for the manufacture of a medicament comprising the steps of the method for the identification of a compound inhibiting CD95 signaling and the further step of formulating the inhibiting compound as a medicament. | 11-22-2012 |
20120202732 | MODIFIED AAV CAPSID POLYPEPTIDES - The present invention is concerned with the provision of a polynucleotide encoding an AAV capsid polypeptide comprising an inserted peptide and a vector comprising said polynucleotide. Moreover, contemplated is a host cell comprising said polynucleotide or vector, a method for the manufacture of said capsid polypeptide as well as said polypeptide. Further included is an antibody specifically binding to said polypeptide and a medicament comprising said polynucleotide, vector, polypeptide, or antibody. Also contemplated are the use of said polynucleotide, vector, polypeptide, or antibody for the manufacture of a medicament for the treatment of vascular disease and a method for the identification of a compound binding to said polypeptide. | 08-09-2012 |
20110262081 | OPTICAL CONNECTORS AND A METHOD OF PRODUCTION THEREOF - The invention relates to a method for producing an active optical connection with an optoelectronic element and a light deflection means for light deflection between the optoelectronic element and an optical waveguide arranged transversely with respect to the beam direction of said element. In this case, it is provided that a carrier substrate for the optoelectronic element is arranged in a highly precisely repeatably positioning machine, in particular a flip-chip machine, the optoelectronic element is mounted on the substrate by a or the highly precisely repeatably positioning machine and a curable, moldable compound is applied over the optoelectronic element, and the moldable compound is molded by a mold for molding light deflection means, said mold being moved by a or the highly precisely repeatably positioning machine, and at the earliest thereafter the substrate is removed from the or a highly precisely repeatably positioning machine. | 10-27-2011 |
20100087630 | Use of XCR1 for Diagnosing or Monitoring of Immune Tolerance - The invention relates to measuring immunological tolerance in T cells. In particular, the invention provides a method for measuring the tolerance status of a T cell sample, comprising the steps of (a) measuring the expression level of XCR1 (also known as GPR5, which is a receptor for Single C Motif-1/Lymphotactin) in a T cell sample, and (b) comparing the measured expression level with a reference value, said reference value being representative of the expression level of XCR1 in a control T cell sample. The present invention furthermore provides methods, kits and uses to determine the required stringency of immunosuppression, particularly the required dosage of an immunosuppressant. Also provided are methods and uses to identify or validate inducers or inhibitors of immunological tolerance. | 04-08-2010 |
20100068825 | Method and Device for Detecting at Least One Property of at Least One Object with a Microchip - The present invention relates to a method and a device for the detection of at least one property of at least one object. The detection is effected by means of a microchip. The microchip has at least one readable detection pixel. In order to reduce the technical equipment outlay during object detection, the method according to the invention is characterized by the fact that the at least one object is arranged at the microchip in a spatially predetermineable position. The at least one object is exposed to illumination light in order to detect the illumination light that interacts with the at least one object or the light that is induced by the illumination light and emerges from the at least one object by means of the at least one readable detection pixel of the microchip. | 03-18-2010 |
20090263002 | Wave field microscope with sub-wavelength resolution and methods for processing microscopic images to detect objects with sub-wavelength dimensions - The invention relates to a computer implemented method for processing of microscopic images to detect objects of interest. The method includes subjecting the microscopic image to a bandpass filtering to obtain a filtered image, wherein the bandpass filtering is such as to suppress the noise and any objects which are larger than a predetermined size; and processing the filtered image at a plurality of progressively decreasing threshold levels. The processing at each threshold level includes detecting the objects of interest using an object labelling algorithm and removing the detected objects detected at a given threshold level from the working image before proceeding to the next threshold level. | 10-22-2009 |
20090082258 | Means and Methods for Treating Advanced Stage Neuroblastoma - The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases. | 03-26-2009 |
20090048121 | Screening Method for the Early Diagnosis of Cerebral Vasospasm - The invention relates to screening methods and test systems for the in vitro diagnosis and detection of an increased risk of vasospasm in a patient. In addition, the invention describes the use of GAPDH and/or Hsc70 to diagnose an increased risk of vasospasm. Also described is a method for identifying a pharmaceutically active substance for the prevention and/or treatment of cerebral vasospasm and a method for screening a substance library to identify a pharmaceutically active substance for the prevention and/or treatment of cerebral vasospasm. Pharmaceutically active substances and combination preparations are also disclosed. | 02-19-2009 |